Inc. (CIIX) Announces 175% Sales Increase, Launch of Six New Hemp-Infused Skincare Products

  • is a leading financial information website for Chinese-speaking investors
  • The company reported a 175 percent year-over-year increase in revenue for FY2019
  • CIIX’s CBD Biotech Inc. division recently launched six new skincare products Inc. (OTCQB: CIIX) is a foremost financial information website for Chinese-speaking investors in the United States and China. In addition, via its CBD division (CBD Biotech Inc.), the company was focusing on cannabidiol (CBD)-based nutrition and health products. However, the company’s current plan is to return focus to its original mission of providing financial information and services to the larger Chinese community in the United States and elsewhere. Established in 1999, is based in San Gabriel, California (, and it has been operating its premier financial information website for 18 years.

CIIX offers an array of investor education products and services on its main website, The company provides real-time market commentary, analysis and education-related services in Chinese language character sets, including both traditional and simplified. The company also offers its proprietary ChineseInvestors Method, an innovative integration of a disciplined investing process, web-based tools, personalized instructions and support. Therefore, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

Moreover, CIIX provides consultative services to smaller private businesses that are considering going public. The company also provides advertising and public relations-related support services. Additionally, CIIX raises awareness through investor conferences and road shows.

Recently, CIIX provided an update on its financial results for the fiscal year ended May 31, 2019, as well as an outlook for fiscal year 2020 ( The company reported a 175 percent year-over-year increase in revenue for FY2019, with $4,189,935 in sales revenue from industrial hemp and CBD liquor products in FY2019. This number is up from $378,984 in FY2018.

Furthermore, CIIX reported $1,336,402 in investor relations revenues in FY2019, up from $968,282 in FY2018. The company’s subscription revenue in FY2019 was $865,457, up from $779,964 in FY2018. The majority (95 percent) of CIIX’s subscriber base (free and paid members) is located in the United States and Canada. The company’s services are generally delivered to U.S. public and private businesses and also U.S. residents and citizens (

“While we have been strategically focusing on industrial hemp and CBD sales, we are pleased with the progress we have seen in our legacy businesses, financial news, education subscriptions, and investor relations, where we are re-focused on organic growth,” CIIX CEO Warren Wang stated in a news release. “We expect to see the full result of these efforts in FY2020.”

Wang also noted that CIIX hopes for a Nasdaq IPO of CBD Biotech late in FY2019 or early next year. CIIX would then concentrate on identifying an acquisition target for further growth (

In addition, CIIX recently announced that CBD Biotech launched six new products in combination with its long-term strategic plans to expand its hemp/CBD skincare offerings. CBD Biotech’s new products include CBD Oligopeptides Repair Eye Cream, CBD Nerve Acylamide Eye Essence, CBD Hemp Eye Mask, CBD Gold Nicotinamide Essence, CBD Handmade Horse Oil Soap and CBD Clear Bright. These products are designed to complement the company’s present skincare lines and increase brand loyalty and awareness.

CIIX is re-focusing on its legacy business of providing first-rate financial information and services to the larger Chinese community. Of note for investors is that the company anticipates doubling its sales over the next 12 months. CIIX continues to execute on its strategy of solidifying its position as the leading financial information website for Chinese-speaking investors in the U.S. and China.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office


Select A Month

CBDWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722